CO2024016274A2 - Composiciones de receptor de células t en multiplex, terapias combinadas, y sus usos - Google Patents
Composiciones de receptor de células t en multiplex, terapias combinadas, y sus usosInfo
- Publication number
- CO2024016274A2 CO2024016274A2 CONC2024/0016274A CO2024016274A CO2024016274A2 CO 2024016274 A2 CO2024016274 A2 CO 2024016274A2 CO 2024016274 A CO2024016274 A CO 2024016274A CO 2024016274 A2 CO2024016274 A2 CO 2024016274A2
- Authority
- CO
- Colombia
- Prior art keywords
- cell receptor
- multiplexes
- combination therapies
- receptor compositions
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/427—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Data Exchanges In Wide-Area Networks (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263337522P | 2022-05-02 | 2022-05-02 | |
| US202263342451P | 2022-05-16 | 2022-05-16 | |
| US202263413553P | 2022-10-05 | 2022-10-05 | |
| US202263423269P | 2022-11-07 | 2022-11-07 | |
| PCT/US2023/020338 WO2023215183A1 (en) | 2022-05-02 | 2023-04-28 | Multiplexed t cell receptor compositions, combination therapies, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024016274A2 true CO2024016274A2 (es) | 2024-12-09 |
Family
ID=88646870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0016274A CO2024016274A2 (es) | 2022-05-02 | 2024-11-28 | Composiciones de receptor de células t en multiplex, terapias combinadas, y sus usos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250288675A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4519305A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025516264A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250006149A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119487060A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023265422A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3248253A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024016274A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL316250A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024013482A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202406569A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023215183A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024005746A (es) * | 2021-11-10 | 2024-07-19 | Tscan Therapeutics Inc | Peptidos inmunogenicos magea1, proteinas de union que reconocen peptidos inmunogenicos magea1, y usos de estos. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005113595A2 (en) * | 2004-05-19 | 2005-12-01 | Avidex Ltd | High affinity ny-eso t cell receptor |
| ES2635335T3 (es) * | 2010-09-20 | 2017-10-03 | Biontech Cell & Gene Therapies Gmbh | Receptores de células T específicos de antígeno y epítopos de células T |
| NZ741124A (en) * | 2012-07-27 | 2019-11-29 | Univ Illinois | Engineering t-cell receptors |
| JP6895975B2 (ja) * | 2016-01-06 | 2021-06-30 | ヘルス リサーチ インコーポレイテッドHealth Research, Inc. | 組換えt細胞受容体を含む組成物及びライブラリー並びに組換えt細胞受容体を使用する方法 |
| KR20190062505A (ko) * | 2016-10-03 | 2019-06-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | Hpv-특이적 결합 분자 |
| JP7289028B2 (ja) * | 2018-09-05 | 2023-06-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 複数の主要組織適合遺伝子複合体分子に制限したny-eso-1-特異的t細胞受容体の組成物 |
| WO2020167957A1 (en) * | 2019-02-12 | 2020-08-20 | Board Of Regents, The University Of Texas System | High affinity engineered t-cell receptors targeting cmv infected cells |
| DE102019121007A1 (de) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| EP4010377A4 (en) * | 2019-08-09 | 2023-09-06 | A2 Biotherapeutics, Inc. | CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS |
-
2023
- 2023-04-28 EP EP23799850.5A patent/EP4519305A4/en active Pending
- 2023-04-28 US US18/860,341 patent/US20250288675A1/en active Pending
- 2023-04-28 AU AU2023265422A patent/AU2023265422A1/en active Pending
- 2023-04-28 KR KR1020247038208A patent/KR20250006149A/ko active Pending
- 2023-04-28 WO PCT/US2023/020338 patent/WO2023215183A1/en not_active Ceased
- 2023-04-28 CN CN202380051389.XA patent/CN119487060A/zh active Pending
- 2023-04-28 CA CA3248253A patent/CA3248253A1/en active Pending
- 2023-04-28 TW TW112116024A patent/TW202406569A/zh unknown
- 2023-04-28 JP JP2024564522A patent/JP2025516264A/ja active Pending
- 2023-04-28 IL IL316250A patent/IL316250A/en unknown
-
2024
- 2024-10-31 MX MX2024013482A patent/MX2024013482A/es unknown
- 2024-11-28 CO CONC2024/0016274A patent/CO2024016274A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4519305A1 (en) | 2025-03-12 |
| KR20250006149A (ko) | 2025-01-10 |
| IL316250A (en) | 2024-12-01 |
| CN119487060A (zh) | 2025-02-18 |
| EP4519305A4 (en) | 2026-05-06 |
| TW202406569A (zh) | 2024-02-16 |
| JP2025516264A (ja) | 2025-05-27 |
| WO2023215183A1 (en) | 2023-11-09 |
| CA3248253A1 (en) | 2023-11-09 |
| US20250288675A1 (en) | 2025-09-18 |
| AU2023265422A1 (en) | 2024-10-24 |
| MX2024013482A (es) | 2024-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022021676A2 (pt) | Métodos de distribuição de célula in vitro | |
| MX2023000618A (es) | Red neuronal basada en atencion para predecir union, presentacion e inmunogenicidad de peptidos. | |
| UY39488A (es) | Composiciones y métodos para modular la inmunidad mediada por la cadena delta gamma | |
| MX2020008542A (es) | Composiciones y métodos para el suministro de proteínas membranales. | |
| CO2019004630A2 (es) | Composiciones de células t con car anti-bcma | |
| ZA202003386B (en) | Il-2 muteins and uses thereof | |
| CO2021011906A2 (es) | Anticuerpos claudina 6 y usos de los mismos | |
| MX394691B (es) | Moduladores de receptores de quimiocinas y usos de los mismos. | |
| CL2009000245A1 (es) | Compuestos derivados de heterociclil piridinilo, con actividad moduladora del receptor 5-ht6; composicion farmaceutica que los comprende y su uso para tratar la esquizofrenia, ansiedad, migrana, depresion, entre otros. | |
| MX2019011570A (es) | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. | |
| PE20110358A1 (es) | Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias | |
| PE20190173A1 (es) | Receptores de antigenos quimericos y celulas t y metodos de uso | |
| MX2022003885A (es) | Receptores quimericos de citoquinas. | |
| AR119366A1 (es) | Composiciones y métodos para la estimulación con espuma | |
| MX2019010039A (es) | Composiciones y métodos para transducción de tumores. | |
| MX2021002702A (es) | Metodos para expandir celulas t del receptor de antigeno quimerico especificas de antigenos, composiciones y usos relacionados con las mismas. | |
| BR112016023523A2 (pt) | produtos de células t modificados em gene de composição definida | |
| BR112021013971A2 (pt) | Composições e métodos para estimular células natural killer | |
| AR069333A1 (es) | Anticuerpos monoclonales que se unen al receptor tirosin quinasa anexelekto (axl), hibridomas que los producen y sus usos | |
| MX2017003557A (es) | Celulas t de memoria central para terapia adoptiva de celulas t. | |
| PA8638701A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| MX2020003605A (es) | Manipulación del metabolismo de triptamina. | |
| PE20200329A1 (es) | Procedimiento para establecer permisos de usuario en unidad de intercambio de informacion en el sistema | |
| MX2023010969A (es) | Edicion multiplex con enzimas cas. | |
| CR20250427A (es) | Activadores de vías sintéticas |